Comment on

• Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.

  Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan Z, Rackoff WR. Sparano JA, et al. J Clin Oncol. 2009 Sep 20;27(27):4522-9. doi: 10.1200/JCO.2008.20.5013. Epub 2009 Aug 17. J Clin Oncol. 2009. PMID: 19687336 Clinical Trial.